跳到主要內容

臺灣博碩士論文加值系統

(3.235.174.99) 您好!臺灣時間:2021/07/24 20:12
字體大小: 字級放大   字級縮小   預設字形  
回查詢結果 :::

詳目顯示

我願授權國圖
: 
twitterline
研究生:曹正婷
研究生(外文):Jeng-Ting Tsao
論文名稱:活動性全身性紅斑狼瘡病患周邊血液單核球類鐸蛋白受體的表現和功能分析
論文名稱(外文):Expression and Functional Analysis of Toll-like Receptors in Active Systemic Lupus Erythematosus Patients
指導教授:江伯倫江伯倫引用關係
指導教授(外文):Bor-Luen Chiang
學位類別:碩士
校院名稱:國立臺灣大學
系所名稱:臨床醫學研究所
學門:醫藥衛生學門
學類:醫學學類
論文種類:學術論文
論文出版年:2009
畢業學年度:97
語文別:英文
論文頁數:45
中文關鍵詞:全身性紅斑性狼瘡類鐸蛋白受體激素
外文關鍵詞:Systemic lupus erythematosustoll-like receptorcytokine
相關次數:
  • 被引用被引用:0
  • 點閱點閱:171
  • 評分評分:
  • 下載下載:0
  • 收藏至我的研究室書目清單書目收藏:0
紅斑性狼瘡 (Systemic lupus erythematosus, SLE) 患者被發現得到細菌性感染的機率比正常人高。過去研究已知類鐸蛋白受體(toll-like receptors, TLRs)在微生物感染的控制上扮演重要的角色,本研究的主題在比較未治療的SLE病患和正常受試者類鐸蛋白受體的表達量及功能的不同,以探討在免疫力缺陷狀態的SLE病患,類鐸蛋白受體的貢獻為何。類鐸蛋白受體的表達量以流式細胞儀分析後,結果發現CD14巨嗜細胞上TLR2和TLR4的表達量,SLE病患比正常受試者低,TLR9的表達量,SLE病患比正常受試者高。單核球分別以ligands for TLR-2,TLR-4,TLR-9刺激活化,其上清液和血漿利用酵素免疫分析法 (Enzyme-linked immunosorbent assay, ELISA)分析細胞激素的表達量,結果發現經由LPS、CpG ODN、sBLP刺激PBMC生成IL-1和TNF-alpha,在SLE病患均比正常受試者低。由研究結果得知,SLE病患鐸蛋白受體在monocytes的調控和正常受試者不同,以及經由這三種鐸蛋白受體路徑活化的免疫系統在SLE病患製造細胞激素也和正常受試者不同,這可能和SLE病患免疫力缺陷的狀態相關。
SLE patients have been shown to have the higher susceptibility to infectious diseases. Since Toll-like receptors (TLRs) play an important role in controlling microorganism infection, this study has been aimed to compare the expression and function of some TLRs in SLE with those in normal individuals to test the possible contribution of TLRs to the immuno-compromised status in SLE patients. The protein expression levels of TLR-2 TLR-4 and TLR-9 were assayed by flow cytometric analysis, and it was found that, compared with normal individuals, SLE patients expressed the lower levels of TLR-2 and TLR-4, but the higher TLR-9 levels on CD14+ monocytes. The cytokine expression in sera of SLE patients and normal individuals and in the supernatant of lupus and normal PBMCs stimulated with ligands for TLR-2, TLR-4 and TLR-9 were determined by ELISA to be compared the cytokine expression in SLE with those in normal individuals. It was found that PBMCs stimulation by LPS, CpG ODN, and sBLP resulted in attenuated IL-10 and TNF-alpha protein production in SLE patients. These results suggested that the dysregulation of TLRs expression on monocytes and abnormal cytokine production from PBMCs after TLR ligation may be involved in the development of immuno-compromised status in SLE patients.
Content
Acknowledgement i
Abstract(Chinese) ii
Abstract iii
Content iv
List of Figures v
List of Tables vi
Chapter 1 Introduction 1-4
Chapter 2 Material and Methods 5-10
Chapter 3 Results 11-14
Chapter 4 Discussion 15-20
Chapter 5 Conclusion and Perspectives 21
Chapter 6 Reference 22-29
Reference
(1)Bouza E, Moya JG, Munoz P. Infections in systemic lupus erythematosus and rheumatoid arthritis. Infect Dis Clin N Am 2001;15:335-361.
(2)Juarez M, Misischia R, Alarcon GS. Infections in systemic connective tissue disease: systemic lupus erythematosus, scleroderma, and polymyositis / dermatomyositis. Rheum Dis Clin N Am 2003; 29:163-184.
(3)Peter lee, Murray B., Urowitz, Arthur A., M. Bookman, Barry E., Koehler, Hugh A., Smythe, Duncan A., Gordon, and Metro A.,Ogryzlo. A review of 110 cases with particular reference to lupus nephritis, CNS manifestations, infections, aseptic necrosis and prognosis. Quarterly Journal of Medicine 1977;46:1-32.
(4)Rosner S, Ginzler EM, Diamond HS, Weiner M, Schlesinger M, Fries JF, Wasner C, Medsger TA, Zieger G, Klippel JH, Hadler NM, Albert DA, Hess EV, Spencergreen G, Grayzel A, Worth D, Hann BH, Barnett EV. A multi-center study of outcome in systemic lupus erythematosus: II. Causes of death. Arthritis Rheum 1982;25:612-617.
(5)Petri M, Genovese M. Incidence and risk factors for hospitalization in systemic lupus erythematosus. J Rheumatol 1992;19:1559-1565.
(6)Ward MM, Pyun E, Studenski S. Causes of death in systemic lupus erythematosus. Long-term follow up of an inception cohort. Arthritis Rheum 1995;38:1492-1499.
(7)Abu-Shakra M, Urowitz MB, Gladman DD, Gough J. Mortality studies in systemic lupus erythematosus. Results from a single centre. I. Causes of death. J Rheumatol 1995;22:1259-1264.
(8)Mok CC, Lee KW, Ho CTK, Lau CS, Wong RWS. A prospective study of survival and prognostic indicators of systemic lupus erythematosus in a southern Chinese population. Rheumatology 2000;39:399-406.
(9)Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P, Aydintug AO, Jedryka-Goral A, de Ramon E, Fernandez-Nebro A, Galeazzi M, Haga HJ, Mathieu A, Houssiau F, Ruiz-Irastorza G, Ingelmo M, Hughes GRV. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. Medicine 1999;78:167-175.
(10)Blanco FJ, Gomez-Reino JJ, de la Mata J, Corrales A, Rodriquez-Valverde V, Rosas JC, de la Camara AG, Pascual E. Survival analysis of 306 European Spanish patients with systemic lupus erythematosus. Lupus 1998;7:159-163.
(11)Duffy KN, Duffy CM, Gladman DD. Infection and disease actitivity in systemic lupus erythematosus: a review of ospitalized patients. J Rheumatol 1991;18:1180-1184.
(12)Petri M, Genovese M. Incidence of and risk factors for hospitalization in systemic lupus erythematosus. A prospective study of the Hopkins Lupus Cohort. J Rheumatol 1992;19:1559-1565.
(13)Paton NI, Cheong IK, Kong NC, Segasothy M. Risk factors for infection in Malaysian patients with systemic lupus erythematosus. Q J Med 1996;89:531–538.
(14)Zonana-Nacach A, Camargo-Coronel A, Yañez P, Sanchez L, Jimenez- Balderas FJ, Fraga A. Infections in outpatients with systemic lupus erythematosus: a prospective study. Lupus 2001;10:505-510.
(15)Staples PJ, Gerding DN, Decker JL, Gordon RS Jr. Incidence of infection in systemic lupus erythematosus. Arthritis Rheum 1974;17: 1-10.
(16)Lacks S, White P. Morbidity associated with childhood systemic lupus erythematosus. J Rheumatol 1990;17:941-945.
(17)Kahl LE. Herpes Zoster infections in systemic lupus erythematosus: risk factors and outcome. J Rheumatol 1994;21:84-86.
(18)Manzi S, Uller LH, Kutzer J, Pazin GJ, Sinacore J, Medsger TA, Ramseygoldman R. Herpes Zoster in systemic lupus erythematosus. J Rheumatol 1995;22:1254-1258.
(19)Gordon C, Salmon M. Update on systemic lupus erythematosus: autoantibodies and apoptosis. Clinical Medicine, JRCPL 2001;1:10-14.
(20)Jin O, Sun L, Zhou K, Zhang X, Feng X, Mok M, Lau C. Lymphocyte apoptosis and macrophage function: correlation with disease activity in systemic lupus erythematosus. Clinical Rheumatology 24:107-110.
(21)Truneh A, Albert F, Golstein P, Schmitt-Verhulst AM. Early steps of lymphocyte activation bypassed by synergy etween calcium ionophores and phorbol ester. Nature 1985;313:318–320.
(22)Rostaing L, Tkaczuk J, Durand M, Peres C, Durand D, de Preval C, Ohayon E, Abbal M. Kinetics of intracytoplasmic Th1 and Th2 cytokine production assessed by flow cytometry following in vitro activation of peripheral blood mononuclear cells. Cytometry 1999;35:318–328.
(23)Vasselon T, Detmers PA, Charron D, Haziot A. TLR2 recognizes a bacterial lipopeptide through direct binding J Immunol 2004;173:7401-7405.
(24)Cohen CD, Horster S, Sander, CA, Bogner JR. Kaposi’s sarcoma associated with tumour necrosis factor [alpha] neutralizing therapy. Ann Rheum Dis 2003;62:284-285.
(25)Hooks JJ, Moutsopoulos HM, Geis SA, Stahl NI, Decker JL, Notkins AL. Immune interferon in the circulation of patients with autoimmune disease. N. Engl J Med 1979;301:5-8.
(26)Hooks JJ, Jordan GW, Cupps T, Moutsopoulos HM, Fauci AS, Notkins AL. Multiple interferons in the circulation of patients with systemic lupus erythematosus and vasculitis. Arthritis Rheum 1982;25:396–400.
(27)Perni SC, Jean-Pierre C, Bongiovanni AM, Kalish RB, Chasen ST, Witkin SS. Down-regulation of toll-like-receptor-induced pro-inflammatory cytokine activation by cells in the amniotic cavity: a fetal immune defense mechanism against preterm labor Am J Obstet Gynecol 2005;193:S141.
(28)Nagase H, Okugawa S, Ota Y, Yamaguchi M, Tomizawa H, Matsushima K, Ohta K, Yamamoto K, Hirai K. Cytokine-Mediated Regulation of Toll-like Receptor Expression in Eosinophils. J Allergy Clin Immunol 2004;113: S183.
(29)Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357-368.
(30)Alaa A Sabry, Abdalla M Kalil, Mona Abd El-Rahim, Fagr Bazyeed El-Shahat, Sherief Refat Elbasyouni. Proinflammatory cytokines (TNF alpha and IL-6) in Egyptian SLE patients with lupus nephritis-Is it correlated with disease activity? Eur J Gen Med 2005; 2(4):153-158
(31)Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, Schaller JG, Talal N, Winchester RJ. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-1277.
(32)Bombardier C, Gladman D, Urowitz M, Caron D, Chang C. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis Rheum 1992;35:630-640.
(33)Papadimitraki ED, koutala E, Bertsias G, Choulaki C, Kritikos H, Sidiropoulos P, Boumpus DT. TLR-9, but not TLR-2, TLR-3, and TLR-4, is up-regulated from peripheral blood mononuclear cells of patients with active systemic lupus erythematosus. Arthritis Res Ther 2005;7:S52.
(34)Bhan U, Lukacs NW, Osterholzer JJ, Newstead MW, Zeng X, Moore TA, McMillan TR, Krieg AM, Akira S, Standiford TJ. TLR9 is required for protective innate immunity in gram-negative bacterial pneumonia: role of dendritic cells. J Immunol 2007;179:3937-3946.
(35)Gelati M, Lamperti E, Dufour A, Corsini E, Venegoni E, Milanese C, Nespolo A, Salmaggi A. IL-10 production in multiple sclerosis patients, SLE patients and healthy controls: preliminary findings. Ital J of Neurol Sci 1997;18:191-194.
(36)Honda M, Linker-Israeli M. Cytokine gene expression in human systemic lupus erythematosus. In Kammer GM, Tsokos GC (eds): Lupus: Molecular and Cellular Pathogenesis. Totowa, NJ, Humana Press, 1999, p341.
(37)YP Huang, LH Perrin, PA Miescher and RH Zubler. Correlation of T and B cell activities in vitro and serum IL-2 levels in systemic lupus erythematosus. J Immunol 1988; 141: 3: 827-833.
(38)Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheumatol 1996; 35:1067-74.
(39)Herrera-Esparza R, Barbosa-Cisneros O, Villalobos-Hurtado R, Avalos- Diaz E. Renal expression of IL-6 and TNF alpha genes in lupus nephritis. Lupus 1998;7:154-158.
(40)Shakoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359: 579–580
(41)David G. Alleva, Steven B. Kaser and David I. Beller. Intrinsic defects in macrophage IL-12 production associated with immune dysfunction in the MRL/++ and New Zealand black/white F1 lupus-prone mice and the Leishmania major-susceptible BALB/c strain. J Immunol 1998; 161: 6878-6884.
(42)DC Brennan, MA Yui, RP Wuthrich, and VE Kelley. Tumor necrosis factor and IL-1 in New Zealand Black/White mice. Enhanced gene expression and acceleration of renal injury. J Immunol 1989; 143: 3470-3475
(43)Chaim O., Jacob, Frances Hwang, Gail D. Lewis and Alan M. Stall. Tumor necrosis factor alpha in murine systemic lupus erythematosus disease models: Implications for genetic predisposition and immune regulation. Cytokine 1991; 3: 551-561
(44)Christina C, Anderssonb B, Wold AE. Gram-positive and Gram-negative bacteria elicit different patterns of pro-inflammatory cytokines in human monocytes. Cytokine 2005;30:311-318.
QRCODE
 
 
 
 
 
                                                                                                                                                                                                                                                                                                                                                                                                               
第一頁 上一頁 下一頁 最後一頁 top
無相關期刊